Pure Global AI
NCT06146413Not yet recruiting

Triggering Oocyte Maturation in Normoresponders Using Double Trigger or HCG Trigger

Triggering Oocyte Maturation in Normoresponders Using Double Trigger or HCG Trigger . A Randomized Controlled Trial
Bedaya HospitalPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Infertility
Drug/Device/Intervention
Double trigger
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Bedaya Hospital
Location
Giza, Egypt
Timeline & enrollment
Phase
Phase 2
Start date
Dec 30, 2023
End date
Dec 30, 2025
Enrollment
150 participants
Primary outcome

Metaphase-II oocytes rate

Summary

The aim of this study is to compare the efficacy double trigger [ co-administration of GnRH
 agonist with HCG 40 and 34 h prior to ovum pick-up, respectively] with HCG trigger in
 inducing oocyte maturation.

ICD-10 classifications
Female infertilityMale infertilityFemale infertility, unspecifiedFemale infertility of other originFemale infertility of uterine origin
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06146413
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06146413 through Pure Global AI's free database. This Phase 2 trial is sponsored by Bedaya Hospital and is currently Not yet recruiting. The study focuses on Infertility. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.